Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
Authors:
- Rebecca R. VanderpoolRVRebecca R. Vanderpool
- Anastasia GorelovaAGAnastasia Gorelova
- Yiran MaYMYiran Ma
- Mohammad AlhamaydehMAMohammad Alhamaydeh
- Jeffrey BaustJBJeffrey Baust
- Sruti ShivaSSSruti Shiva
- Stevan P. TofovicSTStevan P. Tofovic
- Jian HuJHJian Hu
- Seyed Mehdi NouraieSeyed Mehdi Nouraie
- Mark T. GladwinMGMark T. Gladwin
- Maryam Sharifi-SanjaniMSMaryam Sharifi-Sanjani
- Imad Al GhoulehIGImad Al Ghouleh
Open Access
- 12 May 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5426
Abstract
Prostacyclin analogs are among the most effective and widely used therapies for pulmonary arterial hypertension (PAH). However, it is unknown whether they also confer protection through right ventricle (RV) myocardio-specific mechanisms. Moreover, the use of prostacyclin analogs in severe models of PAH has not been adequately tested. To further identify underlying responses to prostacyclin, a prostacyclin analogue, treprostinil, was used in a preclinical rat Sugen-chronic hypoxia (SuCH) model of severe PAH that closely resembles the human disease. Male Sprague–Dawley rats were implanted with osmotic pumps containing vehicle or treprostinil, injected concurrently with a bolus of Sugen (SU5416) and exposed to 3-week hypoxia followed by 3-week normoxia. RV function was assessed using pressure–volume loops and hypertrophy by weight assessed. To identify altered mechanisms within the RV, tissue samples were used to perform a custom RNA array analysis, histological staining, and protein and transcript level confirmatory analyses. Treprostinil significantly reduced SuCH-associated RV hypertrophy and decreased the rise in RV systolic pressure, mean pulmonary arterial (mPAP), and right atrial (RAP) pressure. Prostacyclin treatment was associated with improvements in RV stroke work, maximum rate of ventricular pressure change (max dP/dt) and the contractile index, and almost a complete reversal of SuCH-associated increase in RV end-systolic elastance, suggesting the involvement of load-independent improvements in intrinsic RV systolic contractility by prostacyclin treatment. An analysis of the RV tissues showed no changes in cardiac mitochondrial respiration and ATP generation. However, custom RNA array analysis revealed amelioration of SuCH-associated increases in newly identified TBX20 as well as the fibrotic markers collagen1α1 and collagen 3α1 upon treprostinil treatment. Taken together, our data support decreased afterload and load-independent improvements in RV function following prostacyclin administration in severe PAH, and these changes appear to associate with improvements in RV fibrotic responses.Keywords
Funding Information
- Investigator Sponsored Study (ISS) (R01HL148712, 15SDG24910003, RG-515656)
- NIH/NHLBI (R01HL148712, 15SDG24910003, RG-515656)
- American Heart Association Scientist Development (R01HL148712, 15SDG24910003, RG-515656)
- American Lung Association Biomedical Research (R01HL148712, 15SDG24910003, RG-515656)
- Vitalant and the Hemophilia Center of Western Pennsylvania (R01HL148712, 15SDG24910003, RG-515656)
- Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute (R01HL148712, 15SDG24910003, RG-515656)
This publication has 41 references indexed in Scilit:
- Metabolic Gene Remodeling and Mitochondrial Dysfunction in Failing Right Ventricular Hypertrophy Secondary to Pulmonary Arterial HypertensionCirculation: Heart Failure, 2013
- Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertensionHistopathology, 2012
- Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte functionJournal of Clinical Investigation, 2011
- Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertensionCritical Care, 2008
- Mutations in Cardiac T-Box Factor Gene TBX20 Are Associated with Diverse Cardiac Pathologies, Including Defects of Septation and Valvulogenesis and CardiomyopathyThe American Journal of Human Genetics, 2007
- Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loopsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Alterations in the Pattern of Collagen Deposition May Contribute to the Deterioration of Systolic Function in Hypertensive Patients With Heart FailureJACC, 2006
- Current options, and long-term results for interventional treatment of pulmonary valvar stenosisCardiology in the Young, 2006
- Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptorAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertensionThe FASEB Journal, 2001